Verve Therapeutics Dividendo
Dividendo criteri di controllo 0/6
Verve Therapeutics does not have a record of paying a dividend.
Informazioni chiave
n/a
Rendimento del dividendo
-46.6%
Rendimento del riacquisto
Rendimento totale per gli azionisti | -46.6% |
Rendimento futuro dei dividendi | 0% |
Crescita dei dividendi | n/a |
Prossima data di pagamento dei dividendi | n/a |
Data di stacco del dividendo | n/a |
Dividendo per azione | n/a |
Rapporto di remunerazione | n/a |
Aggiornamenti recenti sui dividendi
Nessun aggiornamento
Recent updates
Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio
Aug 30Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78
Aug 10We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
Jul 12Why Verve Therapeutics Deserves A Spot On Your Watchlist
Jun 13Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher
May 14The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 12Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
Apr 03Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 28Verve's Proof-Of-Concept Data Doesn't Inspire Confidence
Feb 13Vectoring In On Verve Therapeutics
Jan 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
Jun 07Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 24We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth
Nov 09Verve Therapeutics: Cathie Wood Adds To ARKK
Sep 20Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate
Aug 23Verve Therapeutics falls postmarket on $200M stock offering
Jul 20More CRISPR In Human Subjects
Jul 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
May 11Verve Therapeutics: Early-Stage Biotech With A Large Market
Apr 16Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans
Jan 31Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing
Aug 24Verve Therapeutics jumps 75% in its first day of trading
Jun 17Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: Insufficient data to determine if VERV's dividends per share have been stable in the past.
Dividendo in crescita: Insufficient data to determine if VERV's dividend payments have been increasing.
Rendimento dei dividendi rispetto al mercato
Verve Therapeutics Rendimento dei dividendi rispetto al mercato |
---|
Segmento | Rendimento dei dividendi |
---|---|
Azienda (VERV) | n/a |
Fondo del 25% del mercato (US) | 1.5% |
Top 25% del mercato (US) | 4.5% |
Media del settore (Biotechs) | 2.2% |
Analista previsionale (VERV) (fino a 3 anni) | 0% |
Dividendo notevole: Unable to evaluate VERV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Dividendo elevato: Unable to evaluate VERV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Distribuzione degli utili agli azionisti
Copertura degli utili: Insufficient data to calculate VERV's payout ratio to determine if its dividend payments are covered by earnings.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Unable to calculate sustainability of dividends as VERV has not reported any payouts.